Atlas Trials

Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)

Clinical trial NCT03581942 · COMPLETED

Trial details

NCT number
NCT03581942
Sponsor
Memorial Sloan Kettering Cancer Center
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Start date
2018-08-23
Primary completion
2026-02-05
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.